Table 3.
The association of anti-viral treatment and abnormal liver function test in COVID-19.
| ALT (U/L) | AST (U/L) | TBIL (μmol/L) | ALP (U/L) | GGT (U/L) | ||
|---|---|---|---|---|---|---|
| Umifenovir | No | 34 (20–59) | 26 (18–75) | 10.6 (8.6–13.6) | 54 (47–89) | 34 (19–103) |
| Yes | 34 (20–54) | 31 (23–46) | 10.7 (8.0–14.3) | 53 (43–71) | 29 (19–54) | |
| P-value | 0.670 | 0.826 | 0.857 | 0.174 | 0.417 | |
| Lopinavir /litonavir | No | 33 (20–52) | 29 (22–45) | 10.7 (8.1–14.0) | 53 (43–69) | 28 (19–52) |
| Yes | 41 (23–68) | 39 (29–69) | 9.8 (7.6–15.2) | 52 (42–73) | 45 (24–79) | |
| P-value | 0.060 | ** | 0.744 | 0.893 | ** | |
| Ribavirin | No | 34 (21–56) | 32 (23–47) | 10.6 (8.0–14.0) | 52 (42–69) | 29 (19–54) |
| Yes | 34 (20–64) | 26 (20–46) | 11.6 (8.0–15.3) | 56 (49–87) | 41 (22–78) | |
| P-value | 0.994 | 0.288 | 0.526 | * | 0.186 | |
| Interferon | No | 34 (21–57) | 32 (23–47) | 10.8 (8.1–14.6) | 54 (43–71) | 30 (20–56) |
| Yes | 32 (19–46) | 30 (23–44) | 10.1 (7.7–12.8) | 49 (41–61) | 27 (19–53) | |
| P-value | 0.120 | 0.577 | 0.251 | * | 0.283 |
Data for the level of ALT, AST, TBIL, ALP, and GGT were expressed as median (interquartile range).
*
P < 0.05,
**
P < 0.01. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyltransferase; TBIL, Total bilirubin.